ArticleRespirology case reports2025
A Case Report on the Development of Ulcerative Colitis During Osimertinib Therapy for Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer.
Article in Respirology case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osimertinib, a standard treatment for epidermal growth factor receptor (EGFR)-positive non-small-cell lung cancer, commonly causes manageable diarrhoea. We report osimertinib-induced refractory diarrhoea diagnosed as ulcerative colitis, remitting with mesalazine. A 69-year-old woman with advanced-stage EGFR mutation-positive lung adenocarcinoma developed persistent diarrhoea 3 weeks after starting osimertinib, complicated by anorexia, hypotension, anaemia and renal failure requiring hospitalisation. While anaemia and renal failure improved after osimertinib cessation, diarrhoea persisted. A colonoscopy revealed ulcerative colitis, confirmed by neutrophil and lymphocyte infiltration in the intestinal mucosa, glandular deformation and decreased goblet cells. This case demonstrates that osimertinib-induced ulcerative colitis was successfully treated with mesalazine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.